Lixte Biotechnology Holdings, Inc. Common Stock Stock Prediction
AI-powered sentiment analysis and prediction trends for LIXT, updated each market day.
LIXT AI Sentiment
AI predicts Lixte Biotechnology Holdings, Inc. Common Stock stock is likely to decrease over the next 10 market days.
Prediction date: April 10, 2026
Subscribers see precise scores, buy/sell targets, and full analytics.
About Lixte Biotechnology Holdings, Inc. Common Stock
Lixte Biotechnology Holdings Inc is a clinical-stage biopharmaceutical and proton cancer therapy company focused on identifying new targets for cancer drug development and developing and commercializing cancer therapies. The company's drug product pipeline is focused on inhibitors of protein phosphatase 2A, which is used to enhance cytotoxic agents, radiation, immune checkpoint blockers and other cancer therapies. Its product is LB-100 for Ovarian Clear Cell Carcinoma and Metastatic Colon Cancer. The company operates in a single reportable segment, which consists of the development of cancer treatments.
Sector
Exchange
Market Cap
$33,692,037
Cap Tier
Employees
3
Headquarters
BOCA RATON, FL
Listed Since
Sept. 5, 2007
Website
LIXT Sentiment Trend — Last 30 Predictions
Sentiment zones: Bullish · Neutral · Bearish
LIXT Volatility
Lixte Biotechnology Holdings, Inc. Common Stock has shown high price volatility over the last 5 trading days. High volatility means larger price swings — this can present both opportunity and risk for traders.
